{"nctId":"NCT02625974","briefTitle":"A Study to Learn How Well Nifurtimox Works and How Safe it is in Children Aged 0 to 17 Years With Chagas' Disease, an Inflammatory, Infectious Disease Caused by the Parasite Trypanosoma Cruzi","startDateStruct":{"date":"2016-01-27","type":"ACTUAL"},"conditions":["Chagas Disease"],"count":330,"armGroups":[{"label":"Nifurtimox 60 days / Arm 1","type":"EXPERIMENTAL","interventionNames":["Drug: Nifurtimox (Lampit, BAYA2502)"]},{"label":"Nifurtimox 30 days / Arm 2","type":"EXPERIMENTAL","interventionNames":["Drug: Nifurtimox (Lampit, BAYA2502)","Drug: Placebo"]}],"interventions":[{"name":"Nifurtimox (Lampit, BAYA2502)","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nPart 1:\n\n* Male and female pediatric subjects aged 0 days to younger than 18 years\n* Chagas' disease diagnosed/ confirmed for a) Subjects \\< 8 months of age at randomization must demonstrate direct observation of Trypanosoma cruzi by concentration test; b) Subjects ≥ 8 months to \\< 18 years of age at randomization must demonstrate a positive conventional ELISA result for both recombinant ELISA and total purified antigen ELISA\n\nPart 2:\n\n\\- Male and female subjects who were randomized and received at least one dose of their assigned 60- or 30-day regimen of nifurtimox treatment\n\nExclusion Criteria:\n\nPart 1:\n\n* Subjects aged 0 to 27 days who, at birth, were pre-term, weighed less than 2500 g, or had a maximum Apgar score \\< 7 at 5 minutes\n* Known evidence of Chagas' disease-related cardiomyopathy/ Chagas' heart disease\n* Known evidence of Chagas' disease-related gastrointestinal dysfunction (e.g. megaoesophagus, megacolon, or both) or Chagas' digestive disease\n* Serious manifestations of acute Chagas' disease, including myocarditis, meningoencephalitis, or pneumonitis\n* Known evidence of Chagas' disease-related damage to the peripheral nervous system or peripheral neuropathy\n* Clinically significant psychiatric disorder (e.g. moderate to severe depression, severe anxiety, or psychosis) or epilepsy\n* Subjects with contraindications/ warnings to nifurtimox administration, or with conditions that may increase the risk of the undesirable effects of nifurtimox\n* Subjects who have had previous treatment with trypanocidal agents or an accepted indication for antiparasitic therapy (e.g. reactivation of Chagas' infection due to immunosuppression by several diseases or treatment with steroids)\n* Subjects living in housing conditions where there is no active or effective vector control to Trypanosoma cruzi reinfection as determined by Ministry of Health guidelines in each country\n\nPart 2:\n\n* Subjects with acute or chronic health conditions or congenital disorders which, in the opinion of the investigator, would make them unsuitable for participation in the clinical study\n* Subjects living in housing conditions where there is no active or effective vector-control to Trypanosoma cruzi reinfection as determined by Ministry of Health guideline of the respective country\n* Subjects with clinical manifestations of Chagas' disease-related gastrointestinal dysfunction or serious manifestations of acute Chagas' disease\n* Immuno-compromised subjects (e.g. with human immunodeficiency virus or treated with immunosuppressive drugs)","healthyVolunteers":false,"sex":"ALL","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Part 1 - Percentage of Sero-reduction or Sero-conversion (Cured Subjects)","description":"Cure is defined as sero-reduction (in subjects ≥8 months to \\<18 years of age at randomization) or sero-conversion (in all subjects). Sero-reduction is defined as a ≥20% reduction in optical density \\[OD\\]) measured by two conventional ELISA serology tests and sero-conversion is defined as negative Immunoglobulin G (IgG) concentration measured by two conventional ELISA serology tests.\n\nSubjects who have missing conventional serology results at the 12 month time point were treated as failures (ie, no cure).\n\nFor the primary objective in the study, superiority over placebo was confirmed if the lower limit of the 95% Confidence Interval (CI) for the nifurtimox (60-day regimen) cure rate is greater than 16%, the larger of the upper limits of the 95% CIs for historical placebo control.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.9","spread":null},{"groupId":"OG001","value":"18.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Part 2 - Incidence Rate of Seronegative Conversion in Subjects Received at Least One Dose of the 60-day Nifurtimox Treatment Regimen.","description":"Seronegative conversion measured by two types of assay (recombinant ELISA and indirect hemagglutination assay \\[IHA\\]) in subjects who were randomized and received at least one dose of the 60-day nifurtimox treatment regimen compared to an external control group of historical placebo patients with Chagas' disease. Incidence rate is the number of new cases of seronegative conversion over the study period (i.e., 4 years after end of nifurtimox treatment) divided by the person-time at risk. It was modelled using a Poisson distribution with a 2-sided 95% exact CI.\n\nNumber of participants with events were reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1 - Nifurtimox Concentration Over Time in Plasma at Visit 2","description":"Measured in sub-population.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"21.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.2","spread":null},{"groupId":"OG001","value":"49.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"215.4","spread":null},{"groupId":"OG001","value":"300.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"267.6","spread":null},{"groupId":"OG001","value":"289.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1 - Nifurtimox Concentration Over Time in Plasma at Visit 3","description":"Measured in sub-population.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.7","spread":null},{"groupId":"OG001","value":"38.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.6","spread":null},{"groupId":"OG001","value":"56.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"250.6","spread":null},{"groupId":"OG001","value":"232.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"497.2","spread":null},{"groupId":"OG001","value":"257.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"427.5","spread":null},{"groupId":"OG001","value":"267.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1 - Nifurtimox Concentration Over Time in Plasma at Visit 6","description":"The evaluation was based on clinical examinations. Measured in sub-population.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.8","spread":null},{"groupId":"OG001","value":"40.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.7","spread":null},{"groupId":"OG001","value":"73.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"135.0","spread":null},{"groupId":"OG001","value":"172.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"369.5","spread":null},{"groupId":"OG001","value":"103.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"249.7","spread":null},{"groupId":"OG001","value":"165.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1 - Nifurtimox Concentration Over Time in Plasma at Visit 8","description":"Measured in sub-population.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.4","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"139.1","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"395.6","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"300.6","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 2 - Incidence Rate of Seronegative Conversion in Subjects Who Received at Least One Dose of the 30-day Nifurtimox Treatment Regimen","description":"Seronegative conversion measured by two types of assay (recombinant ELISA and indirect hemagglutination assay \\[IHA\\]) in subjects who were randomized and received at least one dose of the 30-day nifurtimox treatment regimen. Incidence rate is the number of new cases of seronegative conversion over the study period (i.e., 4 years after end of nifurtimox treatment) divided by the person-time at risk. It was modelled using a Poisson distribution with a 2-sided 95% exact CI.\n\nNumber of participants with events were reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 2 - ECG Signs of Established Chagas-related Cardiomyopathy","description":"Summary of subjects by evidence of established Chagas-related cardiomyopathy as measured by electrocardiogram (ECG).\n\nEvidence of established Chagas-related cardiomyopathy: Total","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"189","spread":null},{"groupId":"OG001","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 2 - Serological Response of Established Chagas-related Cardiomyopathy","description":"Summary of subjects by evidence of established Chagas-related cardiomyopathy as measured by Serological response.\n\nEvidence of established Chagas-related cardiomyopathy: Total","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"176","spread":null},{"groupId":"OG001","value":"84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1 + Part 2 - Serial Reduction of Optical Density Values Measured by Total Purified Antigen ELISA","description":"Summary and change from baseline of optical density values measured by total purified antigen ELISA.\n\nOptical density is the measure of absorbance, and is defined as the ratio of the intensity of light falling upon a material and the intensity transmitted.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.47","spread":"0.55"},{"groupId":"OG001","value":"1.52","spread":"0.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.24","spread":"0.62"},{"groupId":"OG001","value":"1.30","spread":"0.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.24","spread":"0.29"},{"groupId":"OG001","value":"-0.23","spread":"0.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.23","spread":"0.59"},{"groupId":"OG001","value":"1.29","spread":"0.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.25","spread":"0.41"},{"groupId":"OG001","value":"-0.23","spread":"0.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.16","spread":"0.58"},{"groupId":"OG001","value":"1.23","spread":"0.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.30","spread":"0.42"},{"groupId":"OG001","value":"-0.30","spread":"0.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.12","spread":"0.57"},{"groupId":"OG001","value":"1.23","spread":"0.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.35","spread":"0.40"},{"groupId":"OG001","value":"-0.30","spread":"0.46"}]}]}]},{"type":"SECONDARY","title":"Part 1 + Part 2 - Serial Reduction of Optical Density Values Measured by Recombinant ELISA","description":"Summary and change from baseline of optical density values measured by recombinant ELISA.\n\nOptical density is the measure of absorbance, and is defined as the ratio of the intensity of light falling upon a material and the intensity transmitted.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.74","spread":"0.63"},{"groupId":"OG001","value":"2.73","spread":"0.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.27","spread":"0.98"},{"groupId":"OG001","value":"2.31","spread":"1.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.47","spread":"0.74"},{"groupId":"OG001","value":"-0.41","spread":"0.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"0.95"},{"groupId":"OG001","value":"2.57","spread":"0.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.23","spread":"0.87"},{"groupId":"OG001","value":"-0.17","spread":"0.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.17","spread":"0.98"},{"groupId":"OG001","value":"2.25","spread":"0.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.56","spread":"0.86"},{"groupId":"OG001","value":"-0.45","spread":"0.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.09","spread":"1.01"},{"groupId":"OG001","value":"2.22","spread":"1.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.64","spread":"0.89"},{"groupId":"OG001","value":"-0.48","spread":"0.87"}]}]}]},{"type":"SECONDARY","title":"Part 1 - Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 1","description":"The evaluation was based on clinical examinations.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1 - Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 3","description":"The evaluation was based on clinical examinations.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1 - Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 6","description":"The evaluation was based on clinical examinations.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1 - Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 8","description":"The evaluation was based on clinical examinations.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1 - Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 9","description":"The evaluation was based on clinical examinations.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1 - Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 10","description":"The evaluation was based on clinical examinations.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1 - Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 11","description":"The evaluation was based on clinical examinations.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1 - Number of Subjects With Positive Results in Concentration Test for T. Cruzi (for Subjects <8 Months of Age)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1 - Number of Subjects With a Positive Serological Response Using Non-conventional Enzyme-linked Immunosorbent Assay-F29 (ELISAF29) Test","description":"The non-conventional ELISA-F29 test is considered an early marker of treatment efficacy in chronic Chagas disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"114","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1 - Number of Subjects With Positive Quantitative Polymerase Chain Reaction (qPCR) Results","description":"The qPCR is molecular technique, considered a tool to diagnose acute and congenital Chagas disease, as well as a marker to measure treatment failure when demonstrating positive (detectable) results","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"117","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"171","spread":null},{"groupId":"OG001","value":"86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"207","spread":null},{"groupId":"OG001","value":"105","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"210","spread":null},{"groupId":"OG001","value":"105","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"206","spread":null},{"groupId":"OG001","value":"105","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"205","spread":null},{"groupId":"OG001","value":"102","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1 - Number of Subjects With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)","description":"TEAEs comprised events which first occurred or worsened at or after first application of study drug during the course of the study up to and including 7 days after last application of study drug","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"147","spread":null},{"groupId":"OG001","value":"66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 2 - Number of Subjects With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)","description":"TEAEs comprised events which first occurred or worsened at study start up to end of study in part 2.\n\nIn Part 2, only AEs considered at least possibly related to nifurtimox (administered in part 1) and those caused by protocol-related procedures were reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1 - Number of Subjects With Treatment-emergent High Blood Chemistry Abnormalities by Treatment","description":"The Number Analyzed represents the number of subjects at baseline with a normal or lower than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.\n\nThe number of subjects represents subjects with at least one high laboratory assessment after start of treatment who had a normal or lower than normal laboratory assessment at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1 - Number of Subjects With Treatment-emergent Low Blood Chemistry Abnormalities by Treatment","description":"The number analyzed represents the number of subjects at baseline with a normal or higher than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.\n\nThe number of subjects represents subjects with at least one low laboratory assessment after start of treatment who had a normal or higher than normal laboratory assessment at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1 - Number of Subjects With Treatment-emergent High Hematology Abnormalities by Treatment","description":"The number analyzed represents the number of subjects at baseline with a normal or lower than normal laboratory assessment who also had at least one valid laboratory value after start of treatment. Subjects with missing or high abnormal values at baseline are not included in the number analyzed.\n\nThe number of subjects represents subjects with at least one high laboratory assessment after start of treatment who had a normal or lower than normal laboratory assessment at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1 - Number of Subjects With Treatment-emergent Low Hematology Abnormalities by Treatment","description":"The number analyzed represents the number of subjects at baseline with a normal or lower than normal laboratory assessment who also had at least one valid laboratory value after start of treatment. Subjects with missing or low abnormal values at baseline are not included in the number analyzed.\n\nThe number of subjects represents subjects with at least one low laboratory assessment after start of treatment who had a normal or higher than normal laboratory assessment at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1 - Number of Subjects With Treatment-emergent High Coagulation Abnormalities by Treatment","description":"The Number Analyzed represents the number of subjects at baseline with a normal or lower than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.\n\nThe number of subjects represents subjects with at least one high laboratory assessment after start of treatment who had a normal or lower than normal laboratory assessment at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1 - Number of Subjects With Treatment-emergent Low Coagulation Abnormalities by Treatment","description":"The number analyzed represents the number of subjects at baseline with a normal or higher than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.\n\nThe number of subjects represents subjects with at least one low laboratory assessment after start of treatment who had a normal or higher than normal laboratory assessment at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1 - Number of Subjects With Abnormal Urinalysis Findings Considered as Clinically Significant or Reported as Adverse Events (AEs)","description":"Urinalysis was performed and the following parameters evaluated: bilirubin, blood (red blood cells, white blood cells), chorionic gonadotropin β, glucose, ketones, leukocytes, nitrite, pH, protein, specific gravity, and urobilinogen.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1 - Number of Subjects With Abnormal ECG Findings Considered as Clinically Significant by Investigators","description":"Clinical significance of abnormal ECG was based on the judgement of the investigator","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1 - Mean Changes in Vital Signs (Systolic Blood Pressure) Between the Treatment Groups From Baseline","description":"Systolic Blood Pressure","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.09","spread":"7.79"},{"groupId":"OG001","value":"0.69","spread":"7.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.75","spread":"7.50"},{"groupId":"OG001","value":"-5.00","spread":"7.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.08","spread":"9.98"},{"groupId":"OG001","value":"-0.50","spread":"8.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.74","spread":"10.70"},{"groupId":"OG001","value":"-1.12","spread":"9.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.41","spread":"11.01"},{"groupId":"OG001","value":"0.48","spread":"11.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.13","spread":"11.11"},{"groupId":"OG001","value":"-0.45","spread":"10.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"10.46"},{"groupId":"OG001","value":"-1.48","spread":"10.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.20","spread":"11.52"},{"groupId":"OG001","value":"1.57","spread":"10.70"}]}]}]},{"type":"SECONDARY","title":"Part 1 - Mean Changes in Vital Signs (Diastolic Blood Pressure) Between the Treatment Groups From Baseline","description":"Diastolic Blood Pressure","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"7.72"},{"groupId":"OG001","value":"0.90","spread":"7.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.25","spread":"2.50"},{"groupId":"OG001","value":"-1.00","spread":"2.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.76","spread":"8.36"},{"groupId":"OG001","value":"0.26","spread":"8.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.26","spread":"10.87"},{"groupId":"OG001","value":"-0.14","spread":"10.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"9.91"},{"groupId":"OG001","value":"0.93","spread":"10.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.68","spread":"8.81"},{"groupId":"OG001","value":"-0.21","spread":"10.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.99","spread":"9.90"},{"groupId":"OG001","value":"0.85","spread":"9.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.30","spread":"11.06"},{"groupId":"OG001","value":"3.25","spread":"10.95"}]}]}]},{"type":"SECONDARY","title":"Part 1 - Mean Changes in Vital Signs (Respiratory Rate) Between the Treatment Groups From Baseline","description":"Respiratory Rate","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.12","spread":"4.10"},{"groupId":"OG001","value":"0.47","spread":"2.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.50","spread":"3.42"},{"groupId":"OG001","value":"-1.00","spread":"1.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.05","spread":"3.15"},{"groupId":"OG001","value":"-0.14","spread":"3.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.57","spread":"4.16"},{"groupId":"OG001","value":"-0.06","spread":"3.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.77","spread":"4.04"},{"groupId":"OG001","value":"0.04","spread":"4.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.01","spread":"4.06"},{"groupId":"OG001","value":"-0.50","spread":"3.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.36","spread":"4.50"},{"groupId":"OG001","value":"-0.24","spread":"3.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.93","spread":"5.10"},{"groupId":"OG001","value":"-0.74","spread":"4.61"}]}]}]},{"type":"SECONDARY","title":"Part 1 - Mean Changes in Vital Signs (Heart Rate) Between the Treatment Groups From Baseline","description":"Heart Rate","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.08","spread":"10.19"},{"groupId":"OG001","value":"0.26","spread":"11.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.75","spread":"2.22"},{"groupId":"OG001","value":"-0.75","spread":"2.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"10.11"},{"groupId":"OG001","value":"-0.51","spread":"11.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.78","spread":"11.49"},{"groupId":"OG001","value":"-0.75","spread":"11.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.27","spread":"11.65"},{"groupId":"OG001","value":"-1.34","spread":"11.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.26","spread":"11.97"},{"groupId":"OG001","value":"-1.63","spread":"10.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.28","spread":"11.87"},{"groupId":"OG001","value":"-3.28","spread":"11.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.57","spread":"12.57"},{"groupId":"OG001","value":"-4.66","spread":"14.73"}]}]}]},{"type":"SECONDARY","title":"Part 1 - Mean Changes in Vital Signs (Body Temperature) Between the Treatment Groups From Baseline","description":"Temperature","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.39"},{"groupId":"OG001","value":"0.04","spread":"0.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.35","spread":"0.45"},{"groupId":"OG001","value":"-0.03","spread":"0.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.10","spread":"0.36"},{"groupId":"OG001","value":"0.04","spread":"0.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.06","spread":"0.44"},{"groupId":"OG001","value":"0","spread":"0.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.06","spread":"0.45"},{"groupId":"OG001","value":"0.05","spread":"0.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"0.44"},{"groupId":"OG001","value":"0.02","spread":"0.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.07","spread":"0.49"},{"groupId":"OG001","value":"-0.01","spread":"0.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.14","spread":"0.51"},{"groupId":"OG001","value":"-0.10","spread":"0.50"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Part 1: Number of Participants Cured With 60-day Regimen Compared With Historical Active Control (Benznidazole)","description":"This exploratory efficacy analysis evaluated the cure rate assessed as seroconversion of nifurtimox after 1-year post-treatment follow-up with that of published data for benznidazole (Sosa Estani et al. 1998 and de Andrade et al. 1996) at 4- and 3-year post-treatment follow-up, respectively, used as historical control.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Part 1 - Relationship of Conventional Serology (Total Purified Antigen ELISA) and qPCR Testing by Visit","description":"Using frequencies of matches and mismatches to assess agreement\n\nReactive = Reac ELISA Detectable = Detec qPCR Non-reactive = Nonreac ELISA Non-detectable = Nondetec qPCR Non evaluable = Noneval qPCR qPCR Missing = Miss qPCR Missing conventional testing = Miss ELISA","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"117","spread":null},{"groupId":"OG001","value":"99","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"1","spread":null},{"groupId":"OG005","value":"2","spread":null},{"groupId":"OG006","value":"57","spread":null},{"groupId":"OG007","value":"52","spread":null},{"groupId":"OG008","value":"0","spread":null},{"groupId":"OG009","value":"1","spread":null},{"groupId":"OG010","value":"1","spread":null},{"groupId":"OG011","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"210","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"2","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"1","spread":null},{"groupId":"OG007","value":"103","spread":null},{"groupId":"OG008","value":"0","spread":null},{"groupId":"OG009","value":"1","spread":null},{"groupId":"OG010","value":"2","spread":null},{"groupId":"OG011","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"195","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"11","spread":null},{"groupId":"OG004","value":"2","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"2","spread":null},{"groupId":"OG007","value":"99","spread":null},{"groupId":"OG008","value":"0","spread":null},{"groupId":"OG009","value":"6","spread":null},{"groupId":"OG010","value":"2","spread":null},{"groupId":"OG011","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"194","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"11","spread":null},{"groupId":"OG004","value":"1","spread":null},{"groupId":"OG005","value":"1","spread":null},{"groupId":"OG006","value":"5","spread":null},{"groupId":"OG007","value":"96","spread":null},{"groupId":"OG008","value":"0","spread":null},{"groupId":"OG009","value":"6","spread":null},{"groupId":"OG010","value":"1","spread":null},{"groupId":"OG011","value":"0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Part 1 - Relationship of Conventional Serology (Total Purified Antigen ELISA) and Non-conventional (ELISA-F29) Serologic Testing by Visit","description":"Using frequencies of matches and mismatches to assess agreement\n\nReactive = Reac ELISA Reactive = Reac F29 Non-reactive = Nonreac ELISA Non-reactive = Nonreac F29","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"142","spread":null},{"groupId":"OG001","value":"77","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"72","spread":null},{"groupId":"OG005","value":"38","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"133","spread":null},{"groupId":"OG001","value":"85","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"64","spread":null},{"groupId":"OG005","value":"43","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"131","spread":null},{"groupId":"OG001","value":"83","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"67","spread":null},{"groupId":"OG005","value":"42","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"124","spread":null},{"groupId":"OG001","value":"91","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"63","spread":null},{"groupId":"OG004","value":"63","spread":null},{"groupId":"OG005","value":"43","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"108","spread":null},{"groupId":"OG001","value":"92","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"9","spread":null},{"groupId":"OG004","value":"61","spread":null},{"groupId":"OG005","value":"42","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"106","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"8","spread":null},{"groupId":"OG004","value":"54","spread":null},{"groupId":"OG005","value":"48","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"6","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Part 1 - Relationship of Conventional Serology (Recombinant ELISA) and Non-conventional (ELISA-F29) Serologic Testing by Visit","description":"Using frequencies of matches and mismatches to assess agreement\n\nReactive = Reac ELISA Reactive = Reac F29 Non-reactive = Nonreac ELISA Non-reactive= Nonreac F29","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"142","spread":null},{"groupId":"OG001","value":"77","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"72","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"133","spread":null},{"groupId":"OG001","value":"85","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"64","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"131","spread":null},{"groupId":"OG001","value":"81","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"67","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"124","spread":null},{"groupId":"OG001","value":"90","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"63","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"108","spread":null},{"groupId":"OG001","value":"91","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"10","spread":null},{"groupId":"OG004","value":"59","spread":null},{"groupId":"OG005","value":"2","spread":null},{"groupId":"OG006","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"106","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"53","spread":null},{"groupId":"OG005","value":"1","spread":null},{"groupId":"OG006","value":"6","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Part 1 - Relationship of Conventional Serology (ELISA) to Indirect Hemagglutination Assay (IHA) Results","description":"Sero-reduction is defined as a =\\> 20% reduction in optical density \\[OD\\]) using two conventional ELISA serology tests in subjects =\\> 8 months to \\< 18 years of age at randomization; Others: reactive results that are not sero-reduction in subjects =\\> 8 months to \\< 18 years of age at randomization; or reactive results in subjects \\< 8 months of age at randomization.\n\nNon-reactive ELISA = Nonreac ELISA Non-reactive IHA = Nonreac IHA Reactive IHA decrease = Reac IHA dec React IHA nochange = Reac IHA nochange Reactive ELISA: seroreduction = Reac ELISA reduc Reactive ELISA: others = Reac ELISA other","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"40","spread":null},{"groupId":"OG005","value":"20","spread":null},{"groupId":"OG006","value":"1","spread":null},{"groupId":"OG007","value":"47","spread":null},{"groupId":"OG008","value":"89","spread":null},{"groupId":"OG009","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"12","spread":null},{"groupId":"OG005","value":"4","spread":null},{"groupId":"OG006","value":"1","spread":null},{"groupId":"OG007","value":"30","spread":null},{"groupId":"OG008","value":"58","spread":null},{"groupId":"OG009","value":"0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Part 1 - Relationship Between Conventional ELISA Results in Terms of Cure or No Cure and IHA Results in All Patients","description":"Cure is defined as sero-reduction (in subjects =\\> 8 months to \\< 18 years of age at randomization) or sero-conversion (in all subjects). Sero-reduction is defined as a =\\> 20% reduction in optical density \\[OD\\]) measured by two conventional ELISA serology tests and sero-conversion is defined as negative Immunoglobulin G \\[IgG\\] concentration measured by two conventional ELISA serology tests.\n\nCure = Cure Non reactive/reactive decreasing = Nonreac/reac dec Reactive non-decreasing = Reac nondec No cure = No Cure Missing IHA testing = IHA missing","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"20","spread":null},{"groupId":"OG002","value":"48","spread":null},{"groupId":"OG003","value":"89","spread":null},{"groupId":"OG004","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"29","spread":null},{"groupId":"OG003","value":"58","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":219},"commonTop":["Headache","Vomiting","Nausea","Nasopharyngitis","Decreased appetite"]}}}